Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection

Anne Lamontagne, Ronald E. Long, Mary Ann Comunale, Julie Hafner, Lucy Rodemich-Betesh, Mengjun Wang, Jorge Marrero, Adrian M. Di Bisceglie, Timothy Block, Anand Mehta

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background:Using comparative glycoproteomics, we have previously identified a glycoprotein that is altered in both amount and glycosylation as a function of liver cirrhosis. The altered glycoprotein is an agalactosylated (G0) immunoglobulin G molecule (IgG) that recognizes the heterophilic alpha-gal epitope. Since the alpha gal epitope is found on gut enterobacteria, it has been hypothesized that anti-gal antibodies are generated as a result of increased bacterial exposure in patients with liver disease.Methods:The N-linked glycosylation of anti-gal IgG molecules from patients with fibrosis and cirrhosis was determined and the effector function of anti-bacterial antibodies from over 100 patients examined. In addition, markers of microbial exposure were determined.Results:Surprisingly, the subset of agalactosylated anti-gal antibodies described here, was impaired in their ability to mediate complement mediated lysis and inhibited the complement-mediated destruction of common gut bacteria. In an analysis of serum from more than 100 patients with liver disease, we have shown that those with increased levels of this modified anti-gal antibody had increased levels of markers of bacterial exposure.Conclusions:Anti-gal antibodies in patients with liver cirrhosis were reduced in their ability to mediate complement mediated lysis of target cells. As bacterial infection is a major complication in patients with cirrhosis and bacterial products such as LPS are thought to play a major role in the development and progression of liver fibrosis, this finding has many clinical implications in the etiology, prognosis and treatment of liver disease.

Original languageEnglish (US)
Article numbere64992
JournalPLoS One
Volume8
Issue number6
DOIs
StatePublished - Jun 4 2013

Fingerprint

Bacterial Antibodies
chronic hepatitis C
Hepatitis C virus
Chronic Hepatitis C
Virus Diseases
Viruses
Hepacivirus
Liver
Anti-Idiotypic Antibodies
liver cirrhosis
liver diseases
Liver Cirrhosis
infection
Glycosylation
Liver Diseases
complement
antibodies
Fibrosis
Antibodies
immunoglobulin G

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Lamontagne, A., Long, R. E., Comunale, M. A., Hafner, J., Rodemich-Betesh, L., Wang, M., ... Mehta, A. (2013). Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection. PLoS One, 8(6), [e64992]. https://doi.org/10.1371/journal.pone.0064992

Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection. / Lamontagne, Anne; Long, Ronald E.; Comunale, Mary Ann; Hafner, Julie; Rodemich-Betesh, Lucy; Wang, Mengjun; Marrero, Jorge; Di Bisceglie, Adrian M.; Block, Timothy; Mehta, Anand.

In: PLoS One, Vol. 8, No. 6, e64992, 04.06.2013.

Research output: Contribution to journalArticle

Lamontagne, A, Long, RE, Comunale, MA, Hafner, J, Rodemich-Betesh, L, Wang, M, Marrero, J, Di Bisceglie, AM, Block, T & Mehta, A 2013, 'Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection', PLoS One, vol. 8, no. 6, e64992. https://doi.org/10.1371/journal.pone.0064992
Lamontagne A, Long RE, Comunale MA, Hafner J, Rodemich-Betesh L, Wang M et al. Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection. PLoS One. 2013 Jun 4;8(6). e64992. https://doi.org/10.1371/journal.pone.0064992
Lamontagne, Anne ; Long, Ronald E. ; Comunale, Mary Ann ; Hafner, Julie ; Rodemich-Betesh, Lucy ; Wang, Mengjun ; Marrero, Jorge ; Di Bisceglie, Adrian M. ; Block, Timothy ; Mehta, Anand. / Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection. In: PLoS One. 2013 ; Vol. 8, No. 6.
@article{13d1928e3a934355964b5913194ee35f,
title = "Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection",
abstract = "Background:Using comparative glycoproteomics, we have previously identified a glycoprotein that is altered in both amount and glycosylation as a function of liver cirrhosis. The altered glycoprotein is an agalactosylated (G0) immunoglobulin G molecule (IgG) that recognizes the heterophilic alpha-gal epitope. Since the alpha gal epitope is found on gut enterobacteria, it has been hypothesized that anti-gal antibodies are generated as a result of increased bacterial exposure in patients with liver disease.Methods:The N-linked glycosylation of anti-gal IgG molecules from patients with fibrosis and cirrhosis was determined and the effector function of anti-bacterial antibodies from over 100 patients examined. In addition, markers of microbial exposure were determined.Results:Surprisingly, the subset of agalactosylated anti-gal antibodies described here, was impaired in their ability to mediate complement mediated lysis and inhibited the complement-mediated destruction of common gut bacteria. In an analysis of serum from more than 100 patients with liver disease, we have shown that those with increased levels of this modified anti-gal antibody had increased levels of markers of bacterial exposure.Conclusions:Anti-gal antibodies in patients with liver cirrhosis were reduced in their ability to mediate complement mediated lysis of target cells. As bacterial infection is a major complication in patients with cirrhosis and bacterial products such as LPS are thought to play a major role in the development and progression of liver fibrosis, this finding has many clinical implications in the etiology, prognosis and treatment of liver disease.",
author = "Anne Lamontagne and Long, {Ronald E.} and Comunale, {Mary Ann} and Julie Hafner and Lucy Rodemich-Betesh and Mengjun Wang and Jorge Marrero and {Di Bisceglie}, {Adrian M.} and Timothy Block and Anand Mehta",
year = "2013",
month = "6",
day = "4",
doi = "10.1371/journal.pone.0064992",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection

AU - Lamontagne, Anne

AU - Long, Ronald E.

AU - Comunale, Mary Ann

AU - Hafner, Julie

AU - Rodemich-Betesh, Lucy

AU - Wang, Mengjun

AU - Marrero, Jorge

AU - Di Bisceglie, Adrian M.

AU - Block, Timothy

AU - Mehta, Anand

PY - 2013/6/4

Y1 - 2013/6/4

N2 - Background:Using comparative glycoproteomics, we have previously identified a glycoprotein that is altered in both amount and glycosylation as a function of liver cirrhosis. The altered glycoprotein is an agalactosylated (G0) immunoglobulin G molecule (IgG) that recognizes the heterophilic alpha-gal epitope. Since the alpha gal epitope is found on gut enterobacteria, it has been hypothesized that anti-gal antibodies are generated as a result of increased bacterial exposure in patients with liver disease.Methods:The N-linked glycosylation of anti-gal IgG molecules from patients with fibrosis and cirrhosis was determined and the effector function of anti-bacterial antibodies from over 100 patients examined. In addition, markers of microbial exposure were determined.Results:Surprisingly, the subset of agalactosylated anti-gal antibodies described here, was impaired in their ability to mediate complement mediated lysis and inhibited the complement-mediated destruction of common gut bacteria. In an analysis of serum from more than 100 patients with liver disease, we have shown that those with increased levels of this modified anti-gal antibody had increased levels of markers of bacterial exposure.Conclusions:Anti-gal antibodies in patients with liver cirrhosis were reduced in their ability to mediate complement mediated lysis of target cells. As bacterial infection is a major complication in patients with cirrhosis and bacterial products such as LPS are thought to play a major role in the development and progression of liver fibrosis, this finding has many clinical implications in the etiology, prognosis and treatment of liver disease.

AB - Background:Using comparative glycoproteomics, we have previously identified a glycoprotein that is altered in both amount and glycosylation as a function of liver cirrhosis. The altered glycoprotein is an agalactosylated (G0) immunoglobulin G molecule (IgG) that recognizes the heterophilic alpha-gal epitope. Since the alpha gal epitope is found on gut enterobacteria, it has been hypothesized that anti-gal antibodies are generated as a result of increased bacterial exposure in patients with liver disease.Methods:The N-linked glycosylation of anti-gal IgG molecules from patients with fibrosis and cirrhosis was determined and the effector function of anti-bacterial antibodies from over 100 patients examined. In addition, markers of microbial exposure were determined.Results:Surprisingly, the subset of agalactosylated anti-gal antibodies described here, was impaired in their ability to mediate complement mediated lysis and inhibited the complement-mediated destruction of common gut bacteria. In an analysis of serum from more than 100 patients with liver disease, we have shown that those with increased levels of this modified anti-gal antibody had increased levels of markers of bacterial exposure.Conclusions:Anti-gal antibodies in patients with liver cirrhosis were reduced in their ability to mediate complement mediated lysis of target cells. As bacterial infection is a major complication in patients with cirrhosis and bacterial products such as LPS are thought to play a major role in the development and progression of liver fibrosis, this finding has many clinical implications in the etiology, prognosis and treatment of liver disease.

UR - http://www.scopus.com/inward/record.url?scp=84878643958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878643958&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0064992

DO - 10.1371/journal.pone.0064992

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e64992

ER -